论文部分内容阅读
目的观察华蟾素联合MPT方案治疗多发性骨髓瘤初治患者近期疗效。方法回顾性分析了45例多发性骨髓瘤初治患者,以应用华蟾素与否分为两组。对照组采用MPT方案化疗,治疗组在对照组基础上加用华蟾素注射液,4周为1疗程,3个疗程后观察疗效。结果治疗组有效率为80%,略高于对照组(70%),但无统计学意义(P>0.05)。治疗后治疗组卡氏评分高于对照组(P<0.05),骨痛评分明显低于对照组(P<0.05)。治疗前两组患者CD3+/HLA-DR+表达比例接近,治疗1疗程后CD3+/HLA-DR+水平降低,但两组差异无统计学意义(P>0.05),治疗3疗程后CD3+/HLA-DR+表达有上升趋势,治疗组恢复较快,优于对照组(P<0.05)。华蟾素的副作用主要表现为血管刺激,两组其余不良反应相当,差异无统计学意义(P>0.05)。结论华蟾素对多发性骨髓瘤初治患者的近期疗效无明显提高,但在改善患者生活质量及免疫功能方面具有较好的效果。
Objective To observe the short-term curative effect of cinobufacini and MPT in the treatment of patients with newly diagnosed multiple myeloma. Methods A retrospective analysis of 45 patients with multiple myeloma naïve patients to apply cinobufotalin or not divided into two groups. The control group was treated with MPT chemotherapy. The treatment group was treated with cinobufacini injection on the basis of the control group, 4 weeks for 1 course of treatment, and after 3 courses of treatment, the curative effect was observed. Results The effective rate of the treatment group was 80%, slightly higher than that of the control group (70%), but not statistically significant (P> 0.05). After treatment, the Karnofsky scores in the treatment group were higher than those in the control group (P <0.05), and the pain scores in the treatment group were significantly lower than those in the control group (P <0.05). The proportion of CD3 + / HLA-DR + expression in the two groups before treatment was close, and the level of CD3 + / HLA-DR + decreased after one course of treatment, but there was no significant difference between the two groups (P> 0.05) There is an upward trend, the treatment group recovered faster, better than the control group (P <0.05). Side effects of cinobufacini mainly manifested as vascular irritation, the remaining two groups of adverse reactions was similar, the difference was not statistically significant (P> 0.05). Conclusions Cinobufacini has no significant improvement on the short-term curative effect in patients with newly diagnosed multiple myeloma, but it has a good effect in improving the quality of life and immune function of patients.